Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology
Alexandra BartolomucciCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaMonyse de NóbregaCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaTadhg FerrierCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaKyle DickinsonCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaNivedita KaoreyCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaAmélie NadeauCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaA. CastilloCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, CanadaJulia V. BurnierCancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada. [email protected]
2025en
ABI
Annotatsiya
Circulating tumor DNA (ctDNA) has emerged as a dynamic biomarker in cancer, as evidenced by its increasing integration into clinical practice. Carrying tumor specific characteristics, ctDNA can be used to inform treatment selection, monitor response, and identify drug resistance. In this review, we provide a comprehensive, up-to-date summary of ctDNA in monitoring treatment response with a focus on lung, colorectal, and breast cancers, and discuss current challenges and future directions.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
2 ta iqtibos0 ta foydalanilgan manba